These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17571441)

  • 21. Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
    Fox J; Tiraboschi JM; Herrera C; Else L; Egan D; Dickinson L; Jackson A; Olejniczak N; Back D; Khoo S; Shattock R; Boffito M
    J Acquir Immune Defic Syndr; 2016 Nov; 73(3):252-257. PubMed ID: 27727157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.
    Pulido I; Machmach K; Romero-Sánchez MC; Genebat M; Mendez-Lagares G; Ruiz-Mateos E; Leal M
    J Infect; 2012 Apr; 64(4):417-23. PubMed ID: 22227467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-HIV agents. Maraviroc approved in Canada.
    TreatmentUpdate; 2007; 19(6):1-3. PubMed ID: 18041146
    [No Abstract]   [Full Text] [Related]  

  • 24. Maraviroc.
    Fadel H; Temesgen Z
    Drugs Today (Barc); 2007 Nov; 43(11):749-58. PubMed ID: 18174962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New HIV drug classes on the horizon.
    Opar A
    Nat Rev Drug Discov; 2007 Apr; 6(4):258-9. PubMed ID: 17457997
    [No Abstract]   [Full Text] [Related]  

  • 26. Anti-HIV agents. Access to maraviroc.
    TreatmentUpdate; 2007; 19(3):5-6. PubMed ID: 17575574
    [No Abstract]   [Full Text] [Related]  

  • 27. Optimal use of maraviroc in clinical practice.
    Soriano V; Geretti AM; Perno CF; Fätkenheuer G; Pillay D; Reynes J; Tambussi G; Calvez V; Alcamí J; Rockstroh J
    AIDS; 2008 Nov; 22(17):2231-40. PubMed ID: 18981762
    [No Abstract]   [Full Text] [Related]  

  • 28. Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials.
    Moyle G; Rajicic N; Goodrich J; Mayer H; Valdez H
    AIDS; 2009 Jul; 23(12):1613. PubMed ID: 19622911
    [No Abstract]   [Full Text] [Related]  

  • 29. New drugs: Maraviroc and Lanreotide.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(6):778-83. PubMed ID: 18032144
    [No Abstract]   [Full Text] [Related]  

  • 30. Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
    Waters L; Jackson A; Else L; Rockwood N; Newell S; Back D; Nelson M; Gazzard B; Boffito M
    Antivir Ther; 2015; 20(2):157-63. PubMed ID: 24963558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-2 susceptibility to entry inhibitors.
    Borrego P; Taveira N
    AIDS Rev; 2013; 15(1):49-61. PubMed ID: 23449229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.
    Lê MP; Solas C; Garraffo R; Gagnieu MC; Muret P; Yeni P; Dhiver C; Katlama C; Poizot-Martin I; Durant J; Peytavin G
    J Antimicrob Chemother; 2012 Nov; 67(11):2779-81. PubMed ID: 22773742
    [No Abstract]   [Full Text] [Related]  

  • 34. [Pretreated HIV patients profit from Maraviroc. Oral HIV fusion inhibitor opens new therapy chances].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():52-3. PubMed ID: 19024918
    [No Abstract]   [Full Text] [Related]  

  • 35. Entry inhibitors in the treatment of HIV-1 infection.
    Tilton JC; Doms RW
    Antiviral Res; 2010 Jan; 85(1):91-100. PubMed ID: 19683546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maraviroc first-line therapy for HIV infection. Too risky.
    Prescrire Int; 2010 Nov; 19(110):252-4. PubMed ID: 21284357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma.
    Dufty NE; Gilleran G; Hawkins D; Else LJ; Taylor S
    J Antimicrob Chemother; 2013 Apr; 68(4):972-4. PubMed ID: 23249840
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-HIV agents. One year clinical trial results with maraviroc.
    TreatmentUpdate; 2007; 19(6):3-4. PubMed ID: 18041147
    [No Abstract]   [Full Text] [Related]  

  • 39. Optimizing care for patients on maraviroc salvage therapy.
    Edmunds-Ogbuokiri J
    HIV Clin; 2009; 21(3):11-5. PubMed ID: 19735109
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-HIV agents. Using maraviroc in first-line therapy.
    TreatmentUpdate; 2007; 19(6):5-6. PubMed ID: 18041149
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.